KalVista Pharmaceuticals Gains on Strong Demand for Genetic-Disorder Treatment

Dow Jones

01/09

By Kelly Cloonan

Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter.

The stock rose 14%, to $17.99, in after-hours trading on Thursday. Through market close, shares have surged 92% in the past 12 months.

Chief Executive Ben Palleiko said the company is extremely pleased with its performance since offering Ekterly, an oral treatment for hereditary angioedema, in July.

"Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to Ekterly," Palleiko said.

The Framingham, Mass., company now expects net product revenue of $35 million for the fourth quarter and $49 million for 2025. Analysts polled by FactSet had expected full-year revenue of $32.7 million.

The company is also seeing strong uptake for Ekterly in Germany, Palleiko said, noting early prescribing behaviors in the country have mirrored the positive trends the company saw in the U.S. The company expects to expand into other major markets this year, he added.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

January 08, 2026 18:53 ET (23:53 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2602319748"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602319748\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602319748?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 07:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602319748","market":"fut","top_or_hot":-1,"title":"KalVista Pharmaceuticals Gains on Strong Demand for Genetic-Disorder Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter. \n</p>\n<p>\n  The stock rose 14%, to $17.99, in after-hours trading on Thursday. Through market close, shares have surged 92% in the past 12 months. \n</p>\n<p>\n  Chief Executive Ben Palleiko said the company is extremely pleased with its performance since offering Ekterly, an oral treatment for hereditary angioedema, in July. \n</p>\n<p>\n  \"Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to Ekterly,\" Palleiko said. \n</p>\n<p>\n  The Framingham, Mass., company now expects net product revenue of $35 million for the fourth quarter and $49 million for 2025. Analysts polled by FactSet had expected full-year revenue of $32.7 million. \n</p>\n<p>\n  The company is also seeing strong uptake for Ekterly in Germany, Palleiko said, noting early prescribing behaviors in the country have mirrored the positive trends the company saw in the U.S. The company expects to expand into other major markets this year, he added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 18:53 ET (23:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KalVista Pharmaceuticals Gains on Strong Demand for Genetic-Disorder Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKalVista Pharmaceuticals Gains on Strong Demand for Genetic-Disorder Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-09 07:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter. \n</p>\n<p>\n  The stock rose 14%, to $17.99, in after-hours trading on Thursday. Through market close, shares have surged 92% in the past 12 months. \n</p>\n<p>\n  Chief Executive Ben Palleiko said the company is extremely pleased with its performance since offering Ekterly, an oral treatment for hereditary angioedema, in July. \n</p>\n<p>\n  \"Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to Ekterly,\" Palleiko said. \n</p>\n<p>\n  The Framingham, Mass., company now expects net product revenue of $35 million for the fourth quarter and $49 million for 2025. Analysts polled by FactSet had expected full-year revenue of $32.7 million. \n</p>\n<p>\n  The company is also seeing strong uptake for Ekterly in Germany, Palleiko said, noting early prescribing behaviors in the country have mirrored the positive trends the company saw in the U.S. The company expects to expand into other major markets this year, he added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 18:53 ET (23:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KALV","symbol_name":"Kalvista Pharmaceuticals Inc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2602319748","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602319748","pubTimestamp":1767916380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter.The stock rose 14%, to $17.99, in after-hours trading on Thursday. Through market close, shares have surged 92% in the past 12 months.Chief Executive Ben Palleiko said the company is extremely pleased with its performance since offering Ekterly, an oral treatment for hereditary angioedema, in July.\"Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to Ekterly,\" Palleiko said.The Framingham, Mass., company now expects net product revenue of $35 million for the fourth quarter and $49 million for 2025. Analysts polled by FactSet had expected full-year revenue of $32.7 million.The company is also seeing strong uptake for Ekterly in Germany, Palleiko said, noting early prescribing behaviors in the country have mirrored the ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KALV":"Kalvista Pharmaceuticals Inc","BK4139":"生物科技"},"translate_title":"KalVista Pharmaceuticals因遗传疾病治疗的强劲需求而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KALV":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of KalVista Pharmaceuticals climbed after the company said it saw strong demand for Ekterly, a treatment for a rare genetic disorder, in its latest quarter. \n\n\n  The stock rose 14%, to $17.99, in after-hours trading on Thursday. Through market close, shares have surged 92% in the past 12 months. \n\n\n  Chief Executive Ben Palleiko said the company is extremely pleased with its performance since offering Ekterly, an oral treatment for hereditary angioedema, in July. \n\n\n  \"Fundamental demand has remained strong, with some effects from seasonal variability, and we are encouraged by the continued high level of interest in switching to Ekterly,\" Palleiko said. \n\n\n  The Framingham, Mass., company now expects net product revenue of $35 million for the fourth quarter and $49 million for 2025. Analysts polled by FactSet had expected full-year revenue of $32.7 million. \n\n\n  The company is also seeing strong uptake for Ekterly in Germany, Palleiko said, noting early prescribing behaviors in the country have mirrored the positive trends the company saw in the U.S. The company expects to expand into other major markets this year, he added. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 18:53 ET (23:53 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}